Creative Biolabs is a leading name in the biotechnology industry, renowned for its cutting-edge products and services that cater to the diverse needs of researchers and pharmaceutical companies. With a focus on antibody discovery, development, and engineering, Creative Biolabs has established itself as a pioneer in the field.

Products and Services

Creative Biolabs offers a wide range of products and services designed to support various stages of research and development. Some of their key offerings include:

• Recombinant Antibody Products: These antibodies are engineered for high specificity and affinity, making them ideal for research, diagnostic, and therapeutic applications.
• Engineered Antibody Products: Creative Biolabs provides antibodies with enhanced properties, such as increased stability and improved biological activity.
• Gene Therapy Products: Their gene therapy products include recombinant viruses and antisense oligonucleotides, which are essential tools for gene therapy research.
• Microfluidics: Creative Biolabs also specializes in microfluidic devices, which are used for precise fluid handling and analysis in biomedical research.

Product Uses

The products from Creative Biolabs are utilized in a variety of applications, including:

• Therapeutic Development: Engineered antibodies and therapeutic proteins are used to develop treatments for diseases such as cancer, autoimmune disorders, and infectious diseases.
• Diagnostic Tools: Recombinant antibodies and assay kits are employed in diagnostic tests to detect and measure biomarkers associated with various diseases.
• Research: Antibody libraries and single-domain antibodies are valuable resources for researchers studying protein interactions, disease mechanisms, and drug discovery.
• Gene Therapy: Recombinant viruses and antisense oligonucleotides are used to deliver genetic material into cells for therapeutic purposes.

Publications and Achievements

Creative Biolabs has a strong presence in the scientific community, with numerous peer-reviewed publications and patents. Their research has been cited in various journals, highlighting their contributions to the field of biotechnology. Some notable publications include:

• Antibody Discovery and Development: Studies on the generation and optimization of antibodies for therapeutic and diagnostic use.
• Gene Therapy Research: Publications on the use of recombinant viruses and antisense oligonucleotides in gene therapy.
• Microfluidics: Research on the application of microfluidic devices in drug discovery and biomedical analysis.

Creative Biolabs continues to push the boundaries of biotechnology with its innovative products and services. For more information, visit their website at https://www.creative-biolabs.com/.

Enzymes are biological catalysts that speed up chemical reactions in living organisms. They are essential for many biological processes, such as digestion, metabolism, and immunity. Enzymes are also widely used in various industries, such as food, agriculture, and biofuels. However, one of the most promising and exciting applications of enzymes is in the pharmaceutical industry, where they can help discover, develop, and manufacture new drugs.

Enzymes have many advantages over traditional chemical catalysts, such as high specificity, selectivity, efficiency, and environmental friendliness. However, natural enzymes are not always suitable for industrial applications, as they may have low stability, activity, or compatibility with the desired reaction conditions or substrates. Therefore, scientists have developed methods to engineer enzymes to improve their performance and create novel functions.

One of the leading companies in the field of enzyme engineering is Codexis, Inc., which uses state-of-the-art protein engineering technology to create customized enzymes and processes for the pharmaceutical industry. Codexis leverages the latest breakthroughs in genomics, proteomics, data analytics, high throughput robotics, and computational modeling to rapidly develop highly efficient enzymes, optimized for specific molecules and challenging process conditions¹.

Codexis has collaborated with many major pharmaceutical companies, such as Merck, Pfizer, GlaxoSmithKline, and Roche, to provide biocatalytic solutions for various drug candidates and products. For example, Codexis developed a novel enzyme for the synthesis of sitagliptin, the active ingredient in Merck's diabetes drug Januvia, which reduced the number of steps, increased the yield, and eliminated the use of hazardous chemicals in the manufacturing process². Codexis also created a new enzyme for the production of atorvastatin, the active ingredient in Pfizer's cholesterol-lowering drug Lipitor, which improved the purity, efficiency, and cost-effectiveness of the process³.

In addition to improving existing drugs, engineered enzymes can also help discover new drugs by enabling novel chemical transformations that are difficult or impossible to achieve with conventional methods. For instance, Codexis developed a platform for the synthesis of macrocycles, a class of molecules with high potential for drug discovery, but challenging to make with traditional chemistry⁴. Codexis also created a platform for the synthesis of oligonucleotides, a class of molecules that can modulate gene expression, but require complex and expensive synthesis methods⁵.

The global enzymes market size was valued at $7.81 billion in 2019, and is projected to reach $12.15 billion by 2027, growing at a CAGR of 5.7% from 2020 to 2027. The pharmaceutical segment is expected to be one of the fastest-growing segments, owing to the increasing demand for new and improved drugs, and the rising adoption of biocatalysis as a green and efficient technology. Some of the key players that operate in the global enzymes market include Novozymes, DSM, DuPont, BASF, Advanced Enzyme Technologies, AB Enzymes, Amano Enzyme, Roche, and Thermo Fisher Scientific.

Engineered enzymes are transforming the pharmaceutical industry by enabling new and better ways to discover, develop, and manufacture drugs. They offer significant benefits in terms of quality, productivity, sustainability, and innovation. As the technology advances and the market expands, engineered enzymes are expected to play a vital role in the future of medicine.

Sources:

1. 55 Enzymes Companies Worldwide | Biotech Careers.
2. Accelerating Drug Development and Manufacturing with Engineered Enzymes
3. Enzymes Market Statistics, Growth Drivers | Forecast - 2031.
4. How enzymes are transforming manufacturing - AOCS.
5. Industrial Enzymes Market - Size, Share & Analysis - Mordor Intelligence.

Enzymes are powerful biocatalysts that can accelerate chemical reactions, enhance selectivity and specificity, and reduce environmental impact. They have been widely used in various industries, such as food, agriculture, and biofuels. However, one of the most promising and exciting applications of enzymes is in the pharmaceutical industry, where they can help discover, develop, and manufacture new drugs.

In this blog post, we will highlight some of the new pharmaceutical enzymes products that are expected to hit the market in 2024, based on the latest research and development trends.

Purifine® phospholipases for oil degumming

Purifine® phospholipases are a family of enzymes that can hydrolyze phospholipids, which are the main impurities in crude vegetable oils. By using Purifine® phospholipases, oil refiners can achieve a higher yield and quality of oil, while reducing the consumption of water, chemicals, and energy. Purifine® phospholipases can also improve the nutritional value and stability of the oil, by removing undesirable components and increasing the content of polyunsaturated fatty acids¹.

Purifine® phospholipases are developed and marketed by DSM, a global leader in enzyme solutions for the oils and fats industry. DSM has recently announced that it will launch a new generation of Purifine® phospholipases in 2024, which will offer improved performance, versatility, and sustainability for oil degumming².

Maxilact® lactases for lactose-free dairy products

Maxilact® lactases are a range of enzymes that can break down lactose, the main sugar in milk, into glucose and galactose. By using Maxilact® lactases, dairy producers can create lactose-free or reduced-lactose dairy products, such as milk, cheese, yogurt, and ice cream, that are suitable for consumers with lactose intolerance or preference. Maxilact® lactases can also enhance the flavor, sweetness, and texture of dairy products, by increasing the content of glucose and galactose³.

Maxilact® lactases are developed and marketed by DSM, a global leader in enzyme solutions for the dairy industry. DSM has recently announced that it will launch a new product, Maxilact® LGi, in 2024, which will be the first lactase enzyme that can produce lactose-free dairy products with no added sugar. Maxilact® LGi will enable dairy producers to meet the growing demand for healthier and tastier dairy products.

Rapidase® pectinases for fruit juice clarification

Rapidase® pectinases are a group of enzymes that can degrade pectin, a complex polysaccharide that is present in the cell walls of fruits and vegetables. By using Rapidase® pectinases, juice manufacturers can clarify fruit juices, by removing the haze and cloudiness caused by pectin. Rapidase® pectinases can also increase the yield and quality of juice, by releasing more juice from the pulp and enhancing the color, flavor, and aroma of the juice.

Conclusion

Enzymes are revolutionizing the pharmaceutical industry by enabling new and better ways to discover, develop, and manufacture drugs. They offer significant benefits in terms of quality, productivity, sustainability, and innovation. As the technology advances and the market expands, enzymes are expected to play a vital role in the future of medicine.

We hope this blog post helps you understand the topic of new pharmaceutical enzymes products. If you have any questions or feedback, please let me know.

Sources:

1. Enzyme research unlocks gateway for new medicines.
2. Enzyme research unlocks gateway for new medicines | CALS
3. How enzymes are transforming manufacturing - AOCS.